Business Context and Reporting Period
Profusa, Inc. (PFSA), a Delaware corporation, filed this Form 8-K on May 22, 2026. The filing reports the entry into a material definitive agreement: a First Amendment to an Asset Purchase Agreement previously dated April 21, 2026, with Bio Insights LLC.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to the transaction value:
- Aggregate Purchase Price: $30,000,000 for the acquisition of the PanOmics Assay platform assets.
- Payment Method: Issuance of a newly created Series A Convertible Preferred Stock.
Material Changes Versus Prior Period
The filing details a specific amendment to the April 21, 2026, Asset Purchase Agreement:
- Deletion of Management Shares: Section 4.6 of the original agreement, which mandated the issuance of common stock equal to 12% of fully diluted shares to the CEO and CFO for retention purposes, has been deleted in its entirety.
- Conforming Changes: Section 3.3(c) was amended to remove references to the Compensation Committee's approval regarding the deleted management share provision.
- Transaction Status: Except for the amendments, the original Asset Purchase Agreement remains in full force and effect.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard legal disclaimer that the description of the amendment is qualified by the full text of the exhibit. The primary focus is the structural change to the equity compensation component of the asset acquisition.
Key Facts for Investor Verification
- Verify the impact of removing the 12% management equity grant on the retention of the CEO and CFO.
- Confirm the terms of the Series A Convertible Preferred Stock issued for the $30 million purchase price.
- Review the full text of the First Amendment (Exhibit 10.1) for any other non-disclosed modifications.
- Assess the strategic rationale for the PanOmics Assay acquisition given the change in management incentives.